Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ethical fallacies, tricky ambiguities, and the misinterpretation of the outcomes in the cranioplasty for mild trigonocephaly.
Ijichi S, Ijichi N, Ishida A, Yotsumoto M, Nagata J, Tanuma R, Imamura C, Toki A, Sakajiri T, Hirotsune H, Nakadoi Y, Tanaka S, Kimura K, Tanaka K. Ijichi S, et al. Among authors: imamura c. Childs Nerv Syst. 2015 Jul;31(7):1009-12. doi: 10.1007/s00381-015-2714-6. Epub 2015 Apr 21. Childs Nerv Syst. 2015. PMID: 25896220 No abstract available.
A concise checklist to determine if the cognitive and/or behavioral changes are attributable to the effect of an intervention.
Ijichi S, Ijichi N, Sameshima H, Kawaike Y, Imamura C, Hazama K, Hirotsune H, Kimura K, Nakadoi Y, Oiji A, Ota J, Sakajiri T, Tanaka S, Tanaka K. Ijichi S, et al. Among authors: imamura c. Childs Nerv Syst. 2017 Sep;33(9):1429-1432. doi: 10.1007/s00381-017-3501-3. Epub 2017 Jul 4. Childs Nerv Syst. 2017. PMID: 28676977 No abstract available.
Hypothetical novel simulations to explain the evolutionary survival of the hypo-reproductive extreme tail in the complex human diversity.
Ijichi S, Kawaike Y, Ijichi N, Ijichi Y, Hirakata M, Yamaguchi Y, Kamachi A, Imamura C, Fushuku S, Nagata J, Tanuma R, Sameshima H, Morioka H. Ijichi S, et al. Among authors: imamura c. Biosystems. 2021 Jun;204:104393. doi: 10.1016/j.biosystems.2021.104393. Epub 2021 Feb 25. Biosystems. 2021. PMID: 33640397 Free article.
Concentrations of Irinotecan and SN-38 in the Ascites and the Fluid Product of Cell-Free and Concentrated Ascites Reinfusion Therapy 9 Days After Administration of Irinotecan in a Patient with Gastric Cancer: A Case Report.
Baba K, Tanie T, Matsubara Y, Hirata Y, Ikematsu H, Imamura CK, Boku N. Baba K, et al. Among authors: imamura ck. Onco Targets Ther. 2024 Nov 20;17:1089-1094. doi: 10.2147/OTT.S486272. eCollection 2024. Onco Targets Ther. 2024. PMID: 39588517 Free PMC article.
Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Murakami M, Miyata Y, Nakashima K, Abe M, Nishimura J, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakamura N, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Nakajima TE. Murakami M, et al. Among authors: imamura ck. Int J Clin Oncol. 2024 Nov 21. doi: 10.1007/s10147-024-02663-4. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39570460
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.
Nakashima K, Harashima S, Kaneko R, Tanaka R, Abe M, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Satomi E, Takeda M, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Sasaki H. Nakashima K, et al. Among authors: imamura ck. Int J Clin Oncol. 2024 Nov 12. doi: 10.1007/s10147-024-02652-7. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39531096
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.
Nakashima K, Yokomizo A, Murakami M, Okita K, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Yamamoto N, Aogi K, Abe M. Nakashima K, et al. Among authors: imamura ck. Int J Clin Oncol. 2024 Dec;29(12):1785-1794. doi: 10.1007/s10147-024-02643-8. Epub 2024 Oct 17. Int J Clin Oncol. 2024. PMID: 39417943
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Yokomizo A, Nakashima K, Iba A, Okita K, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Yamamoto N, Aogi K, Abe M. Yokomizo A, et al. Among authors: imamura ck. Int J Clin Oncol. 2024 Nov;29(11):1632-1640. doi: 10.1007/s10147-024-02624-x. Epub 2024 Sep 28. Int J Clin Oncol. 2024. PMID: 39340704
79 results